• Strategy
  • Payers
  • AI
  • Cybersecurity
  • Device Development
  • Studies/Published Research
  • Ethics
  • Regulatory
  • Digital Biomarkers
  • Data Science
  • Companion Diagnostics
  • Clinical Care
  • Digital Therapeutics
  • Academic Research
  • Virtual Reality
  • RWE
  • Digital Endpoints
  • Medical Devices (Class II and Class III)
  • Commercialization
  • Clinical Trials
  • Drug-Device Combinations
  • SaMD
  • Remote Patient Monitoring
  • Patient Engagement
  • Profiles/Q&A

Veris Health Inc. Launches Cancer Care Platform

Article

The new platform allows patients to access personalized cancer care.

A commercial stage medical technology company launched a new digital platform for remote patient monitoring.

Veris Health Inc. announced in a press release that the platform was live through a joint press release with it’s majority owner, PAVmed Inc. The first group of patient were successfully onboarded to The Veris Cancer Care Platform, allowing them to access personalized cancer care.

The Veris CCP app is available for download through the Apple App Store and Google Play. Patients who enroll in the platform also receive a Bluetooth enabled VerisBox, along with training on using its reporting functions for physiological data.

In the press release, PAVmed’s chairman and CEO Lishan Aklog, M.D., said, “We are very excited that the promise of enhancing personalized cancer care through RPM using our state-of-the-art digital health platform, Veris CCP, has become a reality for cancer patients and their clinicians, Our team together with the New Jersey Cancer Care team flawlessly executed the required technical integration and onboarding processes."

Aklog continued, "Early reports of our platform already having a real impact on clinical care are very gratifying. Our software-as-a-service recurring-revenue business model is now poised to deliver near-term value at attractive margins to both Veris and its clients."

Aklog is also Veris Health Inc.’s executive chairman.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.